Bone health is critically influenced by the balance of growth hormone signalling, with both growth hormone deficiency (GHD) and acromegaly demonstrating significant but contrasting impacts on the ...

Acromegaly is a rare endocrine disorder characterised by the excessive secretion of growth hormone (GH), most frequently resulting from a benign pituitary adenoma. The consequent overproduction of ...

A personalized treatment protocol was more effective for management of acromegaly -- also known as gigantism -- than the usual trial-and-error approach, the ...

Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), ...

Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY TM (paltusotine) ...

Please provide your email address to receive an email when new articles are posted on . An AI model correctly identified 22 of 31 adults as having acromegaly strictly based on voice recordings. The ...

LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a ...

Drugs for the rare hormone disorder acromegaly include older engineered peptides administered as frequent injections. A new FDA approval brings acromegaly patients the choice of a once-daily pill that ...